Viral Loads in Clinical Specimens and SARS Manifestations by Hung, I.F.N. et al.
A retrospective viral load study was performed on clin-
ical specimens from 154 patients with laboratory-confirmed
severe acute respiratory syndrome (SARS); the specimens
were prospectively collected during patients’ illness. Viral
load in nasopharyngeal aspirates (n = 142) from day 10 to
day 15 after onset of symptoms was associated with oxy-
gen desaturation, mechanical ventilation, diarrhea, hepatic
dysfunction, and death. Serum viral load (n = 53) was asso-
ciated with oxygen desaturation, mechanical ventilation,
and death. Stool viral load (n = 94) was associated with
diarrhea, and urine viral load (n = 111) was associated with
abnormal urinalysis results. Viral replications at different
sites are important in the pathogenesis of clinical and labo-
ratory abnormalities of SARS. 
S
evere acute respiratory syndrome (SARS) is an emerg-
ing infectious disease that affected 8,098 persons and
caused 774 deaths from November 1, 2002, to September
26, 2003 (1). A novel coronavirus (SARS-CoV) was con-
sistently isolated from SARS patients in three different
continents independently (2–4). Animal models using
macaque monkeys, ferrets, and domestic cats were estab-
lished (5–7); no extrapulmonary lesions could be identi-
fied in these animals, although virus isolation and reverse
transcription–polymerase chain reaction (RT-PCR) results
for viral RNA from pharyngeal secretions, tracheo-
bronchial secretions, urine, rectal swabs or stool, kidney
tissue or lung tissues were positive. 
Recently, we reported the use of RT-PCR to detect
SARS-CoV RNA from nasopharyngeal aspirates (NPA)
and throat swab, urine, and stool specimens (8). We also
developed quantitative RT-PCR (RT-qPCR) assays using
the LightCycler System (Idaho Technology Inc., Idaho
Falls, ID) to augment the sensitivity of detection (9). The
serial viral load in NPA was also used to monitor clinical
progress and response to antiviral therapy, and viral load in
serum on admission was used as a marker of prognosis
(10–12). Extrapulmonary manifestations, such as hemato-
logic changes, diarrhea, and liver dysfunction are common
in SARS patients but not in animal models (13–15). In this
study, we assayed and analyzed viral load in clinical spec-
imens taken from different anatomical sites from day 10 to
15 after the onset of symptoms to understand the role of
SARS-CoV in the pathogenesis of clinical manifestations
and laboratory test abnormalities in SARS patients.
Patients and Methods 
We included in this quantitative virologic study 154
patients who fulfilled the modified World Health
Organization (WHO) definition of SARS and whose treat-
ment was managed in the United Christian Hospital and
Caritas Medical Centre of Hong Kong Special
Administration Region of China. All patients’ infections
were either serologically confirmed (fourfold rise of indi-
rect immunofluorescent antibody titer in serum taken on
admission and within 28 days of symptom onset) or RT-
PCR was positive for SARS-CoV RNA (confirmed from
their clinical specimens for those who died or did not sero-
convert before day 28). The case definition includes tem-
perature of >38°C, cough or shortness of breath, and new
pulmonary infiltrates shown on chest x-ray or high-resolu-
tion computed tomographic scan in the absence of an alter-
native diagnosis to explain the clinical signs and
symptoms. 
The treatment protocol, clinical manifestations, and
progression of disease in part of this cohort had been pre-
viously reported (10,11,16). In brief, patients were
prospectively monitored for diarrhea, oxygen desaturation,
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nia, renal impairment, liver dysfunction, or abnormal uri-
nalysis during the first 15 days; and death. Diarrhea was
defined as bowel movements >3 times per day for 2 con-
secutive days. Oxygen desaturation was defined as <90%
oxygen saturation measured by pulse oximetry while
breathing room air. Some of these patients later required
mechanical ventilation. Hepatic dysfunction was defined
as a mean level of alanine aminotransferase (ALT), alka-
line phosphatase (ALP), or both, greater than the upper
limit of normal from day 10 to day 15 after onset of symp-
toms. Impaired renal function was defined as a serum cre-
atinine level higher than the reference range on 2
consecutive days. Lymphopenia was defined as an
absolute lymphocyte count <1,000/µL on 2 consecutive
days. Abnormal urinalysis results were defined as protein-
uria (>30 mg/dL), microscopic hematuria (>10 erythro-
cytes/µL), pyuria (>50 leukocytes/µL) on a dipstick test, or
casts in urine (Combur Test, Roche Diagnostics GmbH,
Mannheim, Germany) examined with inverted microscope
by an experienced technician. 
To diagnose SARS-CoV infection, NPA and serum
samples were taken on admission. Convalescent-phase
serum samples were taken between days 7 and 28 after
symptom onset. In all patients, RT-PCR for SARS-CoV
RNA was performed on the NPA collected on admission.
RT-qPCR was performed for patients who had NPA,
serum, stool, and urine specimens collected on days 10 to
15 after the onset of symptoms. All virologic diagnostic
laboratory tests, including viral culture, RT-PCR, RT-
qPCR, and immunofluorescent antibody detection for
immunoglobulin (Ig) G, were performed according to our
previously published protocols (2,10). NPA was obtained
by suction through both nostrils with a Pennine 6 mucus
extractor (Pennine Healthcare, Derby, UK) and mucus
specimen trap (MST-7000, Pennine Healthcare). The
catheter was connected midway between the tip of the nose
and the auditory meatus; it was rotated continuously and
slowly retrieved with intermittent suction at a negative
pressure of 100 mm Hg for 15 s. The procedure was
repeated in the other nostril. Secretions stuck to the lumen
of the catheter were transferred to the mucus trap by flush-
ing with 1 mLof viral transport medium, which consists of
Earle’s Balanced Salt Solution (BioSource International,
Camarillo, CA), 4.4% bicarbonate, 5% bovine serum albu-
min, vancomycin (100 µg/mL), amikacin (30 µg/mL), and
nystatin (40 U/mL). A 10% stool suspension was made by
swirling approximately 1 g of stool in 10 mLof viral trans-
port medium. Midstream urine was collected in a sterile
container. Serum from clotted blood was collected and
stored at 4°C for antibody testing and at –20°C before
RNA extraction. The other specimens were stored at 4°C
before RNA extraction.
RNA from clinical samples was extracted by using the
QIAamp virus RNA mini kit (Qiagen, Cologne, Germany)
as instructed by the manufacturer. For all specimens,
140 µL of the sample was used for RNA extraction, and
extracted RNA was finally eluted in 30 µL of RNase-free
water and stored at –20°C. For the RT-qPCR assay, RNA
and cDNA were generated as described (9). cDNA was
amplified in a 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA) by using TaqMan PCR Core
Reagent kit (Applied Biosystems). In a typical reaction, 2
µL of cDNA was amplified in a 25-µL reaction containing
0.625 U AmpliTaq Gold polymerase (Applied
Biosystems), 2.5 µL of 10x TaqMan buffer A, 0.2 mmol/L
of dNTPs, 5.5 mmol/L of MgCl2, 2.5 U of AmpErase
UNG, and 1x primers-probe mixture (Assays by Design,
Applied Biosystems). The forward primer was 5′-
CAGAACGCTGTAGCTTCAAAAATCT-3′ (correspon-
ding to nt 17,718–17,742 of the SARS-CoV genome), and
the reverse primer was 5′-TCAGAACCCTGTGATGAAT-
CAACAG-3′ (corresponding to nt 17,761–17,785). The
sequence of the reporter probe was 5′-(FAM)TCTGCG-
TAGGCAATCC(NFQ)-3′ (FAM, 6-carboxyfluorescein;
NFQ, nonfluorescent quencher; complementary to nt
17,745–17,760). Reactions were first incubated at 50°C for
2 min, followed by 95°C for 10 min. Reactions were then
thermocycled for 40 cycles (95°C for 15 s, 60°C for
1 min). Plasmids containing the target sequences were
used as standard controls. To monitor the integrity of RNA
extraction for each sample, a housekeeping gene, β-actin,
was detected by real-time RT-PCR with two primers: β-
actin forward, 5′-CCCAAGGCCAACCGCGAGAAGAT-
3′ and reverse, 5′-GTCCCGGCCAGCCAGGTCCAG-3′.
All samples were found to contain detectable β-actin
RNA.
All timed data were calculated from onset of symp-
toms. We compared the viral load in these specimens with
the presence or absence of diarrhea, oxygen desaturation,
mechanical ventilation, lymphopenia, hepatic dysfunction,
abnormal urinalysis findings, and death rate by chi-square
or Fisher exact test for categorical variables and by Mann-
Whitney U test for continuous variables. A two-tailed p
value  < 0.05 was considered significant. Correlation
between the number of anatomic sites with detectable viral
load by RT-qPCR and death rate was calculated by linear
regression. SPSS (version 11.0, SPSS Inc., Chicago, IL)
was used for all analyses. 
Results
Of the 154 SARS patients who satisfied the WHO def-
inition for SARS, their age range was 20–80 years (mean
41.5 years). The male-to-female ratio was 0.60, and 31
(20.1%) were healthcare workers. One hundred and fifty
patients (97.4%) were ethnic Chinese, and 4 (2.6%) were
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days 10 to 15 from individual patients were available:
NPA(n = 142), serum (n =53), stool (n = 94), and urine (n
= 111). All patients had laboratory-confirmed SARS,
either virologically by qualitative RT-PCR in 116 (75.3%)
patients (from 30.5% of NPA, 68.2% of stool samples,
and 26.6% of urine samples), by RT-qPCR in 126 (81.8%)
patients (from 42.3% of NPA, 41.5% of serum samples,
87.2% of stool samples, and 28.8% of urine samples), or
by seroconversion in indirect immunofluorescent anti-
body assay in 136 (88.3%) patients. Six patients who died
before day 28 did not have serologic documentation, and
12 others had not seroconverted by day 28, but all had
SARS confirmed by RT-PCR. Viral cultures were positive
for SARS-CoV in 20 patients from NPA (n = 18), stool
(n = 1), and urine (n = 1).
Besides fever and pulmonary infiltrates shown on x-
ray, peripheral blood lymphopenia was the most common
hematologic abnormality on admission and afterwards
(Table 1). From admission to day 10, the peripheral lym-
phocyte count in all patients decreased. From days 10 to
19, the peripheral lymphocyte count continued to decrease
in patients who ultimately died, whereas in those who sur-
vived, lymphocyte count gradually increased (Figure).
Seroconversion to SARS-CoV antibodies also started at
around day 10. Diarrhea (43.5%) was the most common
extrapulmonary clinical manifestation from days 10 to 15,
followed by hepatic dysfunction (39.0%). Abnormal uri-
nalysis was found in 87 (56.4%) patients, with increased
leukocyte esterase in 49.4%, pyuria in 23%, microscopic
hematuria in 20.1%, and proteinuria in 3.8%. None of the
patients had impaired renal function from admission to day
20. Oxygen desaturation developed in 73 patients (47.4%)
at a mean of 10.2 (standard deviation [SD] = 5.1) days, and
34 patients (22.1%) died from SARS a mean of 32.4 (SD
= 10.6) days after onset of symptoms. Only four patients
were found to have abnormal mean ALP levels from
admission to day 20. Therefore, only the mean ALT level
from days 10 to 20 was analyzed for correlation with viral
load. The mean ALT level between admission and day 10
was also analyzed. However, no significant association
was found between the mean ALT level and the viral loads
from different specimens.
Both the positivity rate (87.2%) and the viral load by
RT-qPCR (6.1 log10 copies/mL) were highest for stool
specimens, followed by NPA (42.3% and 2.4 log10
copies/mL, respectively). Although virus was more fre-
quently detected in serum (41.5%) than urine (28.8%),
their mean viral loads for those specimens were 2.7 log10
copies/mL and 4.4 log10 copies/mL, respectively (Table 2).
More patients with lymphopenia on admission had virus
detectable by RT-qPCR in NPA (p = 0.04, odds ratio [OR]
2.2, 95% confidence interval [CI] 1.7–4.4, data not
shown). Both the positivity rate and the viral load in NPA
were significantly correlated with diarrhea, oxygen desat-
uration, mechanical ventilation, hepatic dysfunction, and
death rate (all p < 0.01) (Tables 3 and 4). A high viral load
in serum was also associated with oxygen desaturation,
mechanical ventilation, hepatic dysfunction, and death (all
p < 0.01) but not with diarrhea or abnormal urinalysis find-
ings. Stool viral load was associated with diarrhea, hepat-
ic dysfunction, abnormal urinalysis results, and death (all
p < 0.01). A higher viral load in urine was significantly
correlated with abnormal urinalysis and with diarrhea
(both p < 0.01). These findings were confirmed by sub-
group analysis of 40 patients with specimen samples taken
from all four sites (NPA, serum, stool, and urine) (Tables 5
and 6). Again, a detectable viral load in NPA and serum
was associated with oxygen desaturation (OR 5.3, 95% CI
1.4–21.1), mechanical ventilation (OR 1.6, 95% CI
1.1–2.4), and death (OR 1.8, 95% CI 1.2–2.7). The stool
viral load was associated with diarrhea (OR 18, 95% CI
2.0–16.3), although a higher viral load in urine was no
longer associated with abnormal urinalysis results.
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Table 1. The dominant clinical features and laboratory 
abnormalities of 154 patients with SARS
a
Clinical feature  On admission (%)  Days 10–15 (%) 
Oxygen desaturation  2 (1.4)  73 (47.4) 
Diarrhea  15 (10.6)  67 (43.5) 
Lymphopenia  105 (68.1)  126 (81.8) 
Hepatic dysfunction  34 (22.1)  60 (39.0) 
Abnormal urinalysis 
findings 
NA 87  (56.4) 
aSARS, severe acute respiratory syndrome; NA, not applicable. 
Figure. Serial change of the mean absolute lymphocyte count and
immunoglobulin (Ig) G seroconversion of severe acute respiratory
syndrome (SARS)–associated coronavirus in 154 SARS patients.In the subgroup analysis of 40 patients who had all
types of specimen available for analysis, 34 had antibody
seroconversion, and 6 died before day 28 without serolog-
ic documentation. Diagnosis of each was confirmed by
qualitative RT-PCR. In this group, the number of anatom-
ic sites with positive RT-qPCR strongly correlated with the
risk for death (Pearson correlation = 0.517, p < 0.0005).
No deaths were associated with negative RT-qPCR at all
sites or just one positive site. Risk for death was 12.5%
with positivity at two sites and 41.7% with positivity at
three sites. The death rate increased to 66.7% if RT-qPCR
was positive at all four sites.
Discussion
Viral load reflects the dynamic interaction between
viral replication and clearance by body defense mecha-
nisms. Examining viral load in SARS patients has been
used to diagnose and monitor progress or response to
antiviral therapy (10,11). We have shown that viral load in
NPApeaked around day 10 (10), with a rapid decrease and
concomitant normalization of lymphocyte count and rise
in serum antibodies to SARS-CoV (Figure). Presence of
virus and viral load in different body fluids may also bear
on possible modes of transmission. Infectivity at day 10,
reflected by a mean peak viral load of 5.8 log 10 copies/mL
and 7.0 log 10 copies/mL in positive specimens of NPAand
stool, respectively, suggested that respiratory droplets and
indirect contact with feces may be important mechanisms
of transmission. Viral load has typically been measured in
NPA and serum at admission as a diagnostic and prognos-
tic tool (10,12,17). Viral load in body fluids other than
NPAand serum has not been studied to elucidate transmis-
sion and pathogenesis of SARS.
The importance of SARS-CoV as a respiratory
pathogen is supported by the strong association of viral
load in NPAwith oxygen desaturation, mechanical ventila-
tion, and death. Unexpectedly, viral load in NPA was also
associated with diarrhea and hepatic dysfunction.
Anecdotal reports of the use of steroids to treat SARS tend
to suggest these extrapulmonary manifestations could be
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Table 2. SARS-CoV and viral load in different clinical specimens taken during days 10 to 15 after the onset of symptoms
a
Clinical specimens 
Mean viral load in log10 copies/mL 
(SD), all specimens 
Mean viral load in log10 copies/mL 
(SD), positive specimens only  Positivity by RT-qPCR (%) 
NPA (n = 142)  2.4 (3.1)  5.8 (1.7)  60/142 (42.3) 
Serum (n = 53)  1.1 (1.4)  2.7 (0.6)  22/53 (41.5) 
Stool (n = 94)  6.1 (3.0)  7.0 (2.1)  82/94 (87.2) 
Urine (n = 111)  1.3 (2.1)  4.4 (1.3)  32/111 (28.8) 
aSARS-CoV, severe acute respiratory syndrome–associated coronavirus; SD, standard deviation; RT-qPCR, quantitative reverse transcription–
polymerase chain reaction; NPA, nasopharyngeal aspirates. 
 
Table 3. Correlation of RT-qPCR of clinical specimens taken during days 10 to 15, and clinical manifestations in 154 patients with 
SARS
a
Diarrhea O2 desaturation  Mechanical ventilation  Death 
Specimen  Y N 
p value; OR  
(CI) Y  N
p value; OR 
(CI) Y  N
p value; OR 
(CI) Y  N 
p value; OR  
(CI) 
NPA (n = 142)                         
RT-qPCR () (n = 60)  37 23  37 23 22 38 24 36
RT-qPCR (–) (n = 82)  32  50 
 0.01; 2.5  
(1.3–5.0)  28 54
 0.01; 3.1 
(1.6–6.2)  4 78
 0.01; 11.3 
(3.6–35.1)  1 81
 0.01; 54  
(7.1–415.0) 
Median viral load (log10 
copies/mL) 
3.2 0  0.02  4.5 0   0.01  6.4 0   0.01  6.5 0   0.01 
Serum (n = 53)                         
RT-qPCR () (n = 22)  12 10  13 9  7 15 8  14
RT-qPCR (–) (n = 31)  13  18 
0.4 
7 24
 0.01; 5  
(1.5–16.4)  0 31
 0.01; 1.5  
(1.1–2.0)  0 31
 0.01; 17.1 
(2.0–151.0) 
Median viral load  
(log10 copies/mL) 
0 0  0.5  2.3 0   0.01  2.6 0   0.01  2.6 0   0.01 
Stool (n = 94)                          
RT-qPCR () (n = 82)  46 36  39 43 16 66 17 65
RT-qPCR (–) (n = 12)   1  11 
 0.01; 14.1 






Median viral load  
(log10 copies/mL) 
7.5 5  0.01  7.2 5 0.1 8  7 0.05  8.3  6.9  0.01 
Urine (n = 111)                         
RT-qPCR () (n = 32)  23 9  15 17 7 25 7 25
RT-qPCR (–) (n = 79)  32  47 
 0.01; 3.8  






Median viral load  
(log10 copies/mL) 
0   0   0.01  0 0  0.7  0 0  0.3  0 0  0.4 
aRT-qPCR, quantitative reverse transcription–polymerase chain reaction; SARS, severe acute respiratory syndrome; Y, yes; N, no; OR, odds ratio; CI, 
95% confidence interval; NPA, nasopharyngeal aspirates part of an inflammatory “spillover” from virus-induced
immune dysfunction or excessive cytokine activation in
the lungs (18). However, our findings suggest that viral
replication in extrapulmonary sites may be important,
since viral load in stool is highly correlated with diarrhea,
and electron microscopy of the ileum and colonic biopsy
specimens from SARS patients showed numerous intracel-
lular and extracellular virus particles (19). High viral load
in urine is also associated with abnormal urinalysis find-
ings. In this regard, SARS-CoV is currently known to
grow only in fetal monkey kidney cells (i.e., fRhK4 or
Vero E6) and the colonic carcinoma cell line (CACO-2).
The correlation of viral load in stool with hepatic dysfunc-
tion is not completely unexpected, since high viral load in
the stool is likely to be associated with significant portal
venous viremia. In fact, viral load in stool is also associat-
ed with death. 
Serum viral load correlates with oxygen desaturation,
mechanical ventilation, and death. This finding is not sur-
prising, since viremia has also been reported in adenovirus,
respiratory syncytial virus (RSV), and rotavirus infections
(20–22). However, viremia is reported to be short-lasting
in mucosal infections. In one study, 5 out of 41 neonates
with positive RSV antigen in nasal wash specimens were
positive for RSV RNA in blood (21). High levels of aden-
ovirus DNA in serum was also associated with death in
children in whom adenovirus infection developed after
allogeneic stem-cell transplantation. Six (86%) of 7 chil-
dren who died of adenovirus infection, compared with 2
(7%) of 29 other patients, had high serum levels of aden-
oviral DNA (p < 0.0001) (20). The lack of association
between viral load and lymphopenia at day 10 can be
explained by the routine use of steroids, which induce
apoptosis of lymphocytes. The apparently inferior per-
formance of serum viral load as a prognostic indicator
could be related to fewer available serum samples in this
cohort. However, 38% of this group of 53 patients had
oxygen desaturation; this proportion is not significantly
different from the 142 patients (46%) who had submitted
nasopharyngeal samples from day 10 to day 15.
Compared with other common viral respiratory dis-
eases, the onset of peak viral load in the nasopharynx  of
SARS patients appears to be delayed. In a prospective
study of viral shedding in nasopharyngeal secretions in
experimental adult RSV infections, as measured by 50%
tissue culture infective dose (TCID50) viral titer or RT-
qPCR, RSV is detected from day 2 to day 12, with a
plateau phase from day 3 to day 8, at a peak viral load of 5
log10 copies/mL (23). In the case of experimental adult
influenza, viral replication in NPA peaked ≈48 hours after
the onset of symptoms and declined sharply thereafter,
with an insignificant amount of viral shedding after day 8.
Peak virus titers in symptomatic volunteers infected with
influenza AH3N2 were 102.5–107.0 TCID50/mLof nasopha-
ryngeal wash. Viral load was positively correlated with
symptoms of fever and malaise as well as the amount of
viral shedding (24). However, the reported low incidence
of viremia and the early peak nasopharyngeal viral load in
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Table 4. Correlation of RT-qPCR clinical specimens taken during days 10 to 15 and laboratory values in 154 patients with SARS
a
Lymphopenia  Hepatic dysfunction  Abnormal urinalysis results 
Specimen  Y  N  p value; OR (CI)  Y  N  p value; OR (CI)  Y  N  p value; OR (CI) 
NPA (n = 142)                   
   RT-qPCR () (n = 60)  56  4  40 20  43 17 
   RT-qPCR (–) (n = 82)  70  12 
0.8 
38 44 
 0.01; 2.5 (1.2-5.2) 
52 30 
0.07 
   Median viral load  
   (log10 copies/mL) 
0 0  0.3  2.7  0   0.01  0 0  0.1 
Serum (n = 53)                   
   RT-qPCR () (n = 22)  20 2  0.7  12  10  1  18 4  1 
   RT-qPCR (–) (n = 31)  26  5    19  12    26  5   
   Median viral load  
   (log10 copies/mL) 
0 0  0.4  0 0  0.9  0 0  0.5 
Stool (n = 94)                    
   RT-qPCR () (n = 82)  75  7  0.2  46 36  0.1  62 20  0.2 
   RT-qPCR (–) (n = 12)  9  3    4  8    7  5   
   Median viral load  
   (log10 copies/mL) 
7.2 8.2  0.5  7.7 6.6   0.01  7.6 3.1   0.01 
Urine (n = 111)                   
   RT-qPCR () (n = 32)  29 3  0.7  20  12  0.2  29 3  0.01; 7.2 (1.6–32.9) 
   RT-qPCR (–) (n = 79)  69  10    38  41    50  29   
   Median viral load  
   (log10 copies/mL) 
0 0  0.3  0 0  0.2  0 0  <  0.01 
aRT-qPCR, quantitative reverse transcription–polymerase chain reaction; SARS, severe acute respiratory syndrome; Y, yes; N, no; OR, odds ratio; CI, 
95% confidence interval; NPA, nasopharyngeal aspirates. 
 these two conditions could be explained by inherent char-
acteristics of viral replication, background IgG and IgA
against cross-reactive homologous antigens from previous
infections, or innate immunity of the host. In many of these
experimental infections in which the profile of viral load in
NPA was documented, volunteers were adults who had
low-level background antibodies and concomitant cell-
mediated immunity against influenza or RSV (23,24).
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Table 5. Correlation of RT-qPCR clinical specimens taken during days 10 to 15, and clinical manifestations in 40 patients with SARS 
who had specimens taken from all four anatomical sites
a
Diarrhea O2 desaturation  Mechanical ventilation  Death 
Specimen  Y N 
p value;  
OR (CI)  Y  N 
p value;     
OR (CI)  Y  N 
p value;       
OR (CI)  Y  N 
p value;       
OR (CI) 
NPA  (n=40)                    
   RT-qPCR () (n = 18)  11  7  0.4  11  7  0.02; 5.3  
(1.4–21.1) 
7 11   0.01; 1.6 
(1.1–2.4) 
8 10  0.01; 1.8 
(1.2–2.7) 
   RT-qPCR (–) (n = 22)  10  12    5  17    0  22    0  22  
   Median viral load         
(log10 copies/mL) 
2.9 0  0.4  5.1 0   0.01  6.4 0   0.01  6.4 0   0.01 
Serum (n = 40)                         
   RT-qPCR () (n = 18)  12  6  0.1  11  7  0.02; 5.3  
(1.4–21.1) 
7 11   0.01; 1.6 
(1.1–2.4) 
8 10  0.01; 1.8 
(1.2–2.7) 
   RT-qPCR (–) (n = 22)  9  13    5  17    0  22    0  22  
   Median viral load  
   (log10 copies/mL) 
2.3 0  0.3  2.4 0  0.02  2.6 0   0.01  2.6 0   0.01 
Stool (n = 40)                         
   RT-qPCR () (n = 30)  20 10   0.01; 18 
(2.0–16.3) 
12 18  1  5  25  1  7 23 0.7 
   RT-qPCR (–) (n = 10)  1  9    4  6    2  8    1  9   
   Median viral load  
   (log10 copies/mL) 
7.8 2.6  <  0.01  7.3 7.2 0.5  8.2 7.2 0.5  8.7 7  0.03 
Urine (n = 40)                         
   RT-qPCR () (n = 9)  6 3  0.5  3 6  0.7  1 8  1  2 7  1 
   RT-qPCR (–) (n = 31)  15  16    13  18    6  25    6  25  
   Median viral load  
   (log10 copies/mL) 
0 0  0.4  0 0  0.6  0 0  0.5  0 0  1 
aRT-qPCR, quantitative reverse transcription–polymerase chain reaction; SARS, severe acute respiratory syndrome; Y, yes; N, no; 
OR, odds ratio; CI, 95% confidence interval; NPA, nasopharyngeal aspirates. 
Table 6. Correlation of RT-qPCR clinical specimens taken during days 10 to 15 and laboratory values in 40 patients with SARS who 
had specimens taken from all four anatomic sites
a
 Lymphopenia  on  s  Hepatic dysfuncti Abnormal urinalysis result
Specimen Y  N  p  value  N  lue  Y  N    Y  p va p value
NPA  (n=40)              
   RT-qPCR () (n = 18)  15  3 0.6  0  8 0.8  16  2   
 1    16  6   
 0  0 0.9  0.8  0   
         
1 0.4
   RT-qPCR (–) (n = 22)  20  2  1 11 
   Median viral load  
   (log10 copies/mL) 
2.9 0  0.9 0.5
Serum (n = 40)     
   RT-qPCR () (n = 18)  16  2  1  0 8  0.8  16 2   
 1    16  6   
 0  0 0.7  1.1  0   
         
1 0.4
   RT-qPCR (–) (n = 22)  19  3  1 11 
   Median viral load  
   (log10 copies/mL) 
0 0 0.6 0.3
Stool (n = 40)     
   RT-qPCR () (n = 30)  27 3  0.6  8  2 0.3 25  5   
 3  7  6  4  
 8  .7  .04  7.8  2.6   
         
1 1 0.2
   RT-qPCR (–) (n = 10)  8  2 
   Median viral load  
   (log10 copies/mL) 
7.9 7.2  0.8 7. 4 0 0.1
Urine (n = 40)     
   RT-qPCR () (n = 9)  8  1  1  7 2  0.1  8 1   
 4    23  8   
  0 0  .06  0 0   
0.7
   RT-qPCR (–) (n = 31)  27  4  1 17 
   Median viral load  
   (log10 copies/mL) 
0 0  1 0 0.4
aRT-qPCR, quantitative reverse transcription–polymerase chain reaction; SARS, severe acute respiratory syndrome; Y, yes; N, no; NPA, nasopharyngeal 
aspirates. Falsely negative serum viral load in influenza or RSV
infection could be related to hemagglutinating properties
of these two viruses, which may remain stuck on the ery-
throcyte in the clotted blood sample. In a novel emerging
infectious disease such as SARS, most of the general pop-
ulation would not have background or partial immunity
(2,25); viremia or a delayed peak viral load at day 10 in
NPA is therefore not completely unexpected. 
One limitation of the present study is its retrospective
nature. Only specimens provided at approximately day 10
could be tested and analyzed. Changes of lymphocyte sub-
sets were also not analyzed. Nonetheless, lymphocyte
changes in SARS patients were well reported by two other
groups who showed a consistent decrease in the peripher-
al blood level of dendritic cell subsets, natural killer cells,
CD4+ and CD8+ T lymphocytes, and B lymphocytes
(26,27). 
SARS is predominantly a respiratory infection, which
possibly spreads through the mucosal lumen or the blood-
stream to extrapulmonary sites where viral replication
leads to nonrespiratory manifestations. Concomitant
immune dysregulation and associated inflammatory dam-
age could accentuate disease progression and death. High
viral load in NPA, with or without high viral load in serum,
is a useful prognostic indicator of respiratory failure or
death. The presence of viral RNA in multiple body sites
also indicates poor prognosis. Early treatment with an
effective antiviral agent before day 10 may decrease the
peak viral load, ameliorate symptoms, and improve out-
come; early treatment may also reduce viral shedding and
thus the risk for transmission. 
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